Clinical Trial Update: Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML [Phase 2]

View source ↗

Summary

Phase 2 trial assessing low-dose venetoclax and azacitidine as front-line therapy for newly diagnosed acute myeloid leukemia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: AML | Phase 2 | Status: COMPLETED